{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:49Z","timestamp":1794248629995,"version":"4.9.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2024AFD422"],"award-info":[{"award-number":["2024AFD422"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2025AFD788"],"award-info":[{"award-number":["2025AFD788"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004421","name":"World Bank Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004421","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270177"],"award-info":[{"award-number":["82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.isci.2026.116746","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:42:49Z","timestamp":1784043769000},"page":"116746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global welfare burden of hematologic malignancies from 2015 to 2023"],"prefix":"10.1016","volume":"29","author":[{"given":"Yeming","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7629-2642","authenticated-orcid":false,"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116746_bib1","article-title":"The Lancet Healthy, L. Ageing populations: unaffordable demography","volume":"3","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.isci.2026.116746_bib2","first-page":"884","article-title":"Response of Global Health Towards the Challenges Presented by Population Aging","volume":"5","author":"Hong","year":"2023","journal-title":"China CDC Wkly."},{"key":"10.1016\/j.isci.2026.116746_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41586-018-0497-0","article-title":"Population dynamics of normal human blood inferred from somatic mutations","volume":"561","author":"Lee-Six","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116746_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","article-title":"Clonal dynamics of haematopoiesis across the human lifespan","volume":"606","author":"Mitchell","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116746_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.116746_bib6","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2666-7568(22)00075-7","article-title":"The health-adjusted dependency ratio as a new global measure of the burden of ageing: a population-based study","volume":"3","author":"Skirbekk","year":"2022","journal-title":"Lancet Healthy Longev."},{"key":"10.1016\/j.isci.2026.116746_bib7","article-title":"Global, regional, and national economic burden of hematologic malignancies (1990-2021) with projections to 2050","volume":"13","author":"Li","year":"2025","journal-title":"Front. Public Health"},{"key":"10.1016\/j.isci.2026.116746_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41375-024-02452-y","article-title":"Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022","volume":"39","author":"Daltveit","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116746_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12672-025-01958-w","article-title":"Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review","volume":"16","author":"Berhan","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.isci.2026.116746_bib10","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.116746_bib11","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2352-3026(25)00051-1","article-title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","volume":"12","author":"Br\u00f6ckelmann","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.isci.2026.116746_bib12","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.ymthe.2024.07.028","article-title":"T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting","volume":"32","author":"Anderson","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.116746_bib13","first-page":"980","article-title":"Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy","volume":"28","author":"Choi","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.isci.2026.116746_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.116746_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41581-025-00948-z","article-title":"Unequal access: the prohibitive costs of new drugs in low- and middle-income countries","volume":"21","author":"Pettifor","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.isci.2026.116746_bib16","article-title":"Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements","volume":"391","author":"Sharma","year":"2025","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.isci.2026.116746_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40273-024-01433-4","article-title":"Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability","volume":"43","author":"Callenbach","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.isci.2026.116746_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17101722","article-title":"Optimising Cancer Medicine in Clinical Practices: Are Neoadjuvant and Adjuvant Immunotherapies Affordable for Cancer Patients in Low- and Middle-Income Countries?","volume":"17","author":"Mahumud","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2026.116746_bib19","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2214-109X(24)00442-X","article-title":"Prices, availability, and affordability of adult medicines in 54 low-income and middle-income countries: evidence based on a secondary analysis","volume":"13","author":"Oldfield","year":"2025","journal-title":"Lancet. Glob. Health"},{"key":"10.1016\/j.isci.2026.116746_bib20","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/CEOR.S44866","article-title":"Challenges in measuring and valuing productivity costs, and their relevance in mood disorders","volume":"5","author":"Lensberg","year":"2013","journal-title":"Clinicoecon. Outcomes Res."},{"key":"10.1016\/j.isci.2026.116746_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40258-018-0416-4","article-title":"Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review","volume":"16","author":"Pike","year":"2018","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.isci.2026.116746_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021","volume":"14","author":"Pan","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.116746_bib23","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S2214-109X(15)70088-4","article-title":"Global economic consequences of selected surgical diseases: a modelling study","volume":"3","author":"Alkire","year":"2015","journal-title":"Lancet. Glob. Health"},{"key":"10.1016\/j.isci.2026.116746_bib24","first-page":"e359","article-title":"Uptake of rituximab biosimilars in Medicare and Medicaid in 2019-2022","volume":"30","author":"Qian","year":"2024","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.isci.2026.116746_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37348","article-title":"Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China: A Systematic Review and Meta-Analysis","volume":"6","author":"Luo","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.isci.2026.116746_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107353","article-title":"Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database","volume":"132","author":"Brunner","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.isci.2026.116746_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-022-01145-7","article-title":"Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective","volume":"40","author":"Pratz","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.isci.2026.116746_bib28","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116746_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051221","article-title":"Advances in the Treatment of Acute Myeloid Leukemia: Implications for Low- and Middle-Income Countries","volume":"13","author":"Morcos-Sandino","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2026.116746_bib30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40487-022-00198-0","article-title":"Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States","volume":"10","author":"Jagannath","year":"2022","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.isci.2026.116746_bib31","first-page":"917","article-title":"Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis","volume":"29","author":"Yang","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.isci.2026.116746_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrclinonc.2016.59","article-title":"Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML","volume":"13","author":"Gorkin","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.116746_bib33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjc.6600452","article-title":"Trends in mortality from Hodgkin's disease in western and eastern Europe","volume":"87","author":"Levi","year":"2002","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.116746_bib34","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-11-0246","article-title":"Sex disparities in cancer mortality and survival","volume":"20","author":"Cook","year":"2011","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.isci.2026.116746_bib35","series-title":"Global Burden of Disease Study 2023 (GBD 2023) Results","year":"2025"},{"key":"10.1016\/j.isci.2026.116746_bib36","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/risa.12366","article-title":"Research Synthesis and the Value per Statistical Life","volume":"35","author":"Robinson","year":"2015","journal-title":"Risk Anal."},{"key":"10.1016\/j.isci.2026.116746_bib37","first-page":"33","article-title":"The value of a statistical life: theoretical and empirical evidence","volume":"1","author":"Johansson","year":"2002","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.isci.2026.116746_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/bca.2018.26","article-title":"Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis","volume":"10","author":"Robinson","year":"2019","journal-title":"J. Benefit-Cost Anal."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226021243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226021243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:06:55Z","timestamp":1794247615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226021243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589004226021243"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116746","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global welfare burden of hematologic malignancies from 2015 to 2023","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116746"}}